Back

Impact of peak provoked left ventricular outflow tract gradients on health-related quality of life in patients with hypertrophic cardiomyopathy: a real-world cross-sectional survey

29 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Improving diagnosis and treatment in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Paulos Gebrehiwet

Cytokinetics, Incorporated, South San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail
Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Clinical Outcomes in Patients with Hypertrophic Cardiomyopathy
Doctor S. Shin (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Mavacamten versus septal ablation: prognostic differences in 1-year cardiovascular events for HOCM with resting LVOTG ≥50 mmHg
Doctor B. Huang (Chongqing, CN)
Abstract Slides Video
Presentation thumbnail
Baseline global longitudinal strain and mechanical dispersion predict ejection fraction decline during mavacamten therapy in obstructive hypertrophic cardiomyopathy
Doctor I. Cergan (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Heterogeneous left atrial strain trajectories during mavacamten therapy in obstructive hypertrophic cardiomyopathy
Doctor D. Jensen (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
MRI-derived wall thickness heterogeneity in hypertrophic cardiomyopathy and in carriers of sarcomeric gene mutations
Doctor R. Licordari (Messina, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Improving diagnosis and treatment in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Prevalence and clinical impact of latent obstruction in hypertrophic cardiomyopathy
9 December 2021
thumbnail
Congress Presentation
Quality of life in patients with heart failure and improved ejection fraction
23 May 2022
thumbnail
Congress Presentation
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM
29 August 2025
thumbnail
Congress Presentation
Initial insights into left ventricular mechanics of hypertrophic cardiomyopathy patients during follow up of mavacamten therapy
13 December 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources